HomeBIOTECHNOLOGY
BIOTECHNOLOGY
Medical Device News Magazine reports breaking biotechnology news in addition to medical device news.
Alchemab Therapeutics Unveils Alzheimer’s Candidate ATLX-1088 Targeting CD33 at the Antibody Industrial Symposium
After identifying common antibodies unique to individuals resilient to Alzheimer's disease, Alchemab identified the target as CD33. By starting with the body's response to disease, as opposed to the target itself, Alchemab's platform inverts the traditional 'target-led' drug discovery process. In effect, the immune system is used as a search function to identify the most important disease modifying targets.
Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors
This proposed change in Valneva’s governance structure will be submitted to the vote of the Company’s shareholders at an Extraordinary General Meeting later this year.
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
The new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology.
Yourgene Health Presents Data Demonstrating Successful Fetal Fraction Enrichment in NIPT Workflows Following Prolonged Blood Storage in EDTA Tubes
Dr Joanne Mason, Chief Scientific Officer at Yourgene Health, said: “The results of Yourgene’s study with Tommy’s and St Mary’s Hospital greatly improve the feasibility of EDTA tube usage in NIPT, particularly in situations where delayed transport of samples between collection site and analysis locations may occur.
Owlstone Medical Presents Data Demonstrating Progress in Development of Breath Biopsy Test for the Early Detection of Lung Cancer
The company announced new data on the development of a screening test for the early detection of lung cancer. The results and research progress were presented in two posters at the EACR 2023 Congress, the annual meeting of the European Association for Cancer Research, held June 12-15 in Torino, Italy.
SMi Discloses £6 Million Seed Funding Round
SMi notes the tnvestment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Nanotein Technologies Launches Revolutionary NK Cell Soluble Activator for Cancer Immunotherapy Research
Nanotein Technologies adds to its best-in-class NanoSpark™ reagent line, with the launch of NanoSpark™ GROW-NK, a high-performance reagent for the ex vivo activation and expansion of Natural Killer cells, in an easy-to-use, feeder cell free format.
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government Contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
“We are pleased to accept this award and collaboration with the U.S. Government to ensure that, as a society, we are better prepared for the next pandemic. This award validates our unique approach of combining antibody development and electrochemical-based diagnostics for a rapid response to save lives and manage infectious disease outbreaks,” stated Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics.
Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections
Greg Merril, co-Founder and CEO of Adaptive Phage Therapeutics: "This investment will allow us to advance our lead clinical programs related to musculoskeletal infections, including prosthetic joint infections and diabetic foot osteomyelitis."
